8-K: Inari Medical Reports 21% Revenue Growth in Q3 2024, Raises Full-Year Guidance

Inari Medical announced a 21% year-over-year revenue increase for the third quarter of 2024, along with an updated full-year revenue guidance.

Summary

• Inari Medical reported a revenue of $153.4 million for the third quarter of 2024, a 21.4% increase compared to $126.4 million in the same quarter of 2023.
• The company's GAAP operating loss was $13.6 million for Q3 2024, a decrease from the $2.1 million operating income in Q3 2023.
• Non-GAAP operating loss was $0.4 million in Q3 2024, compared to a $4.8 million non-GAAP operating income in the same quarter of the previous year.
• Inari's cash, cash equivalents, and short-term investments totaled $112 million as of the end of Q3 2024.
• The company has raised its full-year 2024 revenue guidance to between $601.5 million and $604.5 million, reflecting a growth of approximately 21.9% to 22.5% over 2023.
• Inari continues to anticipate reaching sustained operating profitability in the first half of 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong revenue growth and raised guidance, but tempered by the shift to operating and net losses. The company is growing but not yet profitable.

Positives

• Revenue increased by 21.4% year-over-year, reaching $153.4 million in Q3 2024.
• Gross profit increased to $133.5 million in Q3 2024, up from $111.9 million in Q3 2023.
• The company raised its full-year 2024 revenue guidance, indicating strong performance and future growth.
• The PEERLESS study acceptance and upcoming presentation at TCT highlights the company's clinical advancements.
• The planned full market release of Artix and expansion into Japan and China signal growth opportunities.

Negatives

• GAAP operating loss was $13.6 million in Q3 2024, a decrease from the $2.1 million operating income in Q3 2023.
• Non-GAAP operating loss was $0.4 million in Q3 2024, compared to a $4.8 million non-GAAP operating income in the same quarter of the previous year.
• Gross margin decreased slightly to 87.1% in Q3 2024 from 88.5% in Q3 2023, due to product mix and ramp-up costs.
• Operating expenses increased to $147.1 million in Q3 2024, up from $109.8 million in Q3 2023, driven by personnel and other costs.
• Net loss was $18.4 million for Q3 2024, compared to a net income of $3.2 million in the same period of the prior year.

Risks

• The company experienced an increase in operating expenses, which contributed to an operating loss.
• The decrease in gross margin may indicate potential challenges in maintaining profitability.
• The company's net loss of $18.4 million in Q3 2024 is a significant downturn compared to the net income of $3.2 million in the same period of the prior year.
• The company's future performance is subject to risks and uncertainties as detailed in their SEC filings.

Future Outlook

Inari expects to reach sustained operating profitability in the first half of 2025 and anticipates continued growth through product launches and international expansion.

Management Comments

• Drew Hykes, CEO of Inari Medical, stated that they continue to drive strong performance across the entire Inari portfolio.
• Drew Hykes also mentioned that they have several important catalysts on the horizon, including the PEERLESS data presentation, the full market release of Artix, and expansion into Japan and China.

Industry Context

This announcement reflects Inari's continued growth in the medical device sector, particularly in the treatment of venous and other diseases. The company's expansion into new markets and product launches positions it to compete with other players in the vascular space.

Comparison to Industry Standards

• While Inari's revenue growth of 21.4% is strong, it is important to compare this to other medical device companies in the vascular space, such as Penumbra, which has also shown significant growth in recent quarters.
• The decrease in gross margin from 88.5% to 87.1% should be compared to industry averages to assess if this is a concerning trend or within normal fluctuations.
• The shift from operating income to operating loss needs to be benchmarked against similar companies to understand if this is a company-specific issue or an industry-wide trend.
• The planned expansion into Japan and China is a common strategy for medical device companies seeking growth, and its success will be a key factor in Inari's future performance.

Stakeholder Impact

• Shareholders may be concerned about the shift to operating and net losses, despite the revenue growth.
• Employees may be impacted by the company's expansion and increased headcount.
• Customers will benefit from the company's new products and expanded market reach.
• Suppliers may see increased demand due to the company's growth.

Next Steps

• The company will present the PEERLESS study at the TCT Annual Scientific Symposium on October 29th.
• Inari plans a full market release of Artix following FDA clearance.
• The company intends to offer its solutions in Japan and China.

Key Dates

Keywords

Inari Medical, Medical Devices, Venous Thromboembolism, Vascular Markets, Financial Results, Revenue Growth, Operating Loss, Gross Profit, PEERLESS Study, Artix, FDA Clearance, International Expansion